Diabetes Mellitus Type 2 in Adults Flashcards
What is the accuracy of fasting capillary blood glucose and fasting venous plasma glucose for screening diabetes?
Fasting capillary blood glucose and fasting venous plasma glucose have similar accuracy for screening diabetes.
What are the results of random capillary blood glucose for screening diabetes?
Random capillary blood glucose has inconsistent results for screening diabetes.
What are the generally accepted screening tests for diagnosing prediabetes and type 2 diabetes in adults?
The generally accepted screening tests for diagnosing prediabetes and type 2 diabetes in adults are HbA1c, fasting plasma glucose, 2-hour 75-g oral glucose tolerance test (OGTT), fasting venous plasma glucose, and 2-hour postload glucose levels.
What is the preferred test for diagnosing diabetes in Canada?
The preferred test for diagnosing diabetes in Canada is HbA1c.
What HbA1c value is considered diagnostic for diabetes?
An HbA1c value of ≥ 6.5% is considered diagnostic for diabetes.
According to the ADA, when should patients who are prescribed an atypical antipsychotic be screened for prediabetes and diabetes after beginning the medication?
Patients who are prescribed an atypical antipsychotic should be screened for prediabetes and diabetes 4 months after beginning the medication, or sooner if clinically relevant, and at least annually thereafter.
What is the recommended test to diagnose posttransplantation diabetes mellitus?
The oral glucose tolerance test is the recommended test to diagnose posttransplantation diabetes mellitus.
What is the recommended approach for screening hyperglycemia in patients after organ transplantation?
Perform screening for hyperglycemia in patients after organ transplantation
What is the recommended screening test for cystic fibrosis-related diabetes?
The recommended screening test for cystic fibrosis-related diabetes is an oral glucose tolerance test.
How often should annual monitoring for complications of diabetes be performed after the diagnosis of cystic fibrosis-related diabetes?
Annual monitoring for complications of diabetes should be performed beginning 5 years after the diagnosis of cystic fibrosis-related diabetes.
How should patients with cystic fibrosis-related diabetes be treated?
Patients with cystic fibrosis-related diabetes should be treated with insulin to individualized glycemic goals.
According to ADA recommendations, when should fasting glucose be assessed for patients with HIV infection?
Fasting glucose should be assessed before starting antiretroviral therapy, at the time of changing antiretroviral therapy, and 3-6 months after initiating/changing antiretroviral therapy then annually .
Why is the HbA1c test not recommended for diagnosing diabetes in patients with HIV infection?
The HbA1c test is not recommended as it underestimates glycemia in this population and may present monitoring challenges.
How often should fasting glucose be retested in patients with fasting glucose test results near the diagnostic threshold HIV PT?
Fasting glucose should be retested every 3-6 months to monitor for progression to diabetes.
When should screening tests for diabetes be repeated?
Screening tests for diabetes should be repeated at least **every 3 years **or sooner with symptoms or change in risk, or
annually if the patient is diagnosed with prediabetes.
What is the recommended frequency for repeat screening tests for diabetes in adults with normal results?
Repeat screening tests for diabetes in adults with normal results should be done at least every 3 years or sooner with symptoms or change in risk, according to ADA recommendations.
What are the risk factors that should be considered when screening asymptomatic adults for type 2 diabetes?
The risk factors that should be considered when screening asymptomatic adults for type 2 diabetes include overweight or obesity, having a first-degree relative with diabetes, previous diagnosis of prediabetes, low levels of high-density lipoprotein cholesterol, high triglyceride levels, hypertension, physical inactivity, race or ethnicity at increased risk, history of cardiovascular disease, polycystic ovary syndrome, and other conditions associated with insulin resistance.
What are the recommended criteria for testing to detect type 2 diabetes or prediabetes in asymptomatic adults?
The recommended criteria for testing to detect type 2 diabetes or prediabetes in asymptomatic adults include adults ≥ 35 years old or adults of any age with overweight or obesity (BMI ≥ 25 kg/m2) with ≥ 1 additional risk factor such as a first-degree relative with diabetes, previous diagnosis of prediabetes, low levels of high-density lipoprotein cholesterol, high triglyceride levels, hypertension, physical inactivity, race or ethnicity at increased risk, history of cardiovascular disease, polycystic ovary syndrome, or other conditions associated with insulin resistance.
What is the recommended screening approach for type 2 diabetes in asymptomatic adults?
The recommended screening approach for type 2 diabetes in asymptomatic adults is to perform informal assessment of risk factors or use a validated risk calculator such as the ADA risk test to determine the need for diagnostic testing.
What are some pharmacologic therapies that may reduce progression to diabetes in patients with prediabetes?
Some pharmacologic therapies that may reduce progression to diabetes in patients with prediabetes are alpha-glucosidase inhibitors (acarbose, voglibose), orlistat, liraglutide, and glitazones (pioglitazone, rosiglitazone).
What is the risk associated with glitazones in the treatment of prediabetes?
The use of glitazones (pioglitazone, rosiglitazone) for the treatment of prediabetes is associated with a boxed warning regarding the risk of heart failure.
What is the recommended pharmacologic therapy for adults at high risk of type 2 diabetes?
Metformin therapy is recommended for adults at high risk of type 2 diabetes, particularly for patients who are aged 25-59 years with a body mass index (BMI) of ≥ 35 kg/m2, higher fasting plasma glucose (≥110 mg/dL), and higher HbA1C (≥ 6%), or those with a history of gestational diabetes mellitus.
What is the potential benefit of metformin therapy for preventing type 2 diabetes in adults?
Metformin therapy may reduce the incidence of diabetes in adults at high risk of type 2 diabetes, when used alone or in combination with lifestyle modifications.
What level of evidence supports the use of metformin for the prevention of type 2 diabetes in adults?
The use of metformin for the prevention of type 2 diabetes in adults is supported by DynaMed Level 3 evidence.
What is the first-line treatment for patients with prediabetes?
The first-line treatment for patients with prediabetes is lifestyle interventions, including diet, activity, weight loss, and smoking cessation.
What are the recommended dietary interventions for patients at high risk for type 2 diabetes?
Patients at high risk for type 2 diabetes are recommended to follow a significantly reduced-calorie diet and engage in ≥ 150 minutes/week of moderate-intensity physical activity.
What types of foods should be emphasized in the diet to prevent or manage type 2 diabetes?
The diet should emphasize nutrient-dense foods high in fiber, such as nonstarchy vegetables, fruits, legumes, and whole grains. Dairy products with minimally added sugar are also recommended.
What type of diet is recommended to improve glucose metabolism and reduce cardiovascular disease risk in patients with type 2 diabetes?
A Mediterranean-style diet rich in monounsaturated and polyunsaturated fats is recommended to improve glucose metabolism and reduce cardiovascular disease risk in patients with type 2 diabetes.
What is the recommended action for patients in terms of tobacco use?
Patients are advised to avoid using cigarettes, e-cigarettes, or other tobacco products.
What are some examples of foods rich in omega-3 fatty acids that can help prevent or treat cardiovascular disease?
Examples of foods rich in omega-3 fatty acids include fatty fish, nuts, and seeds.
According to the information provided, does prevention of diabetes delay or prevent complications compared to treatment after diagnosis?
It has not been established that prevention of diabetes delays or prevents complications compared with treatment once diabetes is diagnosed.
What is the evidence for the relation between BMI and mortality in patients with diabetes mellitus type 2?
The evidence is inconsistent for the relation between BMI and mortality in patients with diabetes mellitus type 2.
Does type 2 diabetes increase the likelihood of cognitive impairment in adults?
Yes, type 2 diabetes may increase the likelihood of cognitive impairment in adults.
What are factors contributing to bone abnormalities in patients with type 2 diabetes?
Factors contributing to bone abnormalities in patients with type 2 diabetes include cellular and molecular mechanisms such as low bone turnover, altered calcium and parathyroid hormone metabolism, proinflammatory state, oxidative stress, advanced glycation end products, loss of incretin effect, increased bone marrow adiposity, dysregulation of adipokines, altered insulin-like growth factor-1 signaling, and certain medications like thiazolidinediones and sodium-glucose cotransporter-2 inhibitors.
Which medication used in the treatment of type 2 diabetes may cause bone loss at the hip?
Canagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, may cause bone loss at the hip in patients with type 2 diabetes.
What are some cellular and molecular mechanisms contributing to bone abnormalities in patients with type 2 diabetes?
Some cellular and molecular mechanisms contributing to bone abnormalities in patients with type 2 diabetes include low bone turnover, altered calcium and parathyroid hormone metabolism, proinflammatory state, oxidative stress, accumulation of advanced glycation end products, loss of incretin effect, increased bone marrow adiposity, dysregulation of adipokines, and altered insulin-like growth factor-1 (IGF-1) signaling.
Do patients with type 2 diabetes have an increased risk of fractures?
Yes, patients with type 2 diabetes have an increased risk of fractures.
What type of fractures are patients with type 2 diabetes at an increased risk for?
Patients with type 2 diabetes are at an increased risk for hip fractures, particularly.
What is limited joint mobility syndrome?
Limited joint mobility syndrome is a condition characterized by stiffness, contractures, and impairment of joint function.
What are some clinical presentations of limited joint mobility syndrome?
Clinical presentations of limited joint mobility syndrome include pain, paresthesia, waxy and thick skin around the fingers, fixed flexion contractures of hand joints, and impaired fine motor and grip strength in the hands.
What are some examination findings associated with limited joint mobility syndrome?
Examination findings may include a positive ‘prayer sign’ (inability to press opposed palms together) or positive ‘tabletop sign’ (inability to make contact with the table at 1 spot when hands are flat on the table and forearm is at a 90-degree angle).
What are the potential long-term effects of limited joint mobility syndrome?
Long-term progression of limited joint mobility syndrome may result in impairment of other joints such as the ankle, spine, shoulder, and hip.
What types of cancer are associated with type 2 diabetes?
Liver, pancreas, endometrium, colon/rectum, breast, and bladder.
What are some risk factors for hypoglycemia in patients with type 2 diabetes?
Risk factors for hypoglycemia in patients with type 2 diabetes include treatment with insulin or insulin secretagogues, problems with kidney or hepatic function, increased duration of diabetes, older age and frailty, cognitive impairment, hypoglycemia unawareness/impaired counterregulatory response, impaired behavioral response to hypoglycemia due to physical or intellectual disability, use of alcohol, polypharmacy, including ACE inhibitors, ARBs, and nonselective beta-blockers, and history of a severe hypoglycemic event.
What is the association between severe hypoglycemia and cognitive function in patients with type 2 diabetes?
Severe hypoglycemia is associated with impaired cognitive function in patients with type 2 diabetes.
What are some factors that contribute to the severity of hypoglycemia in patients with type 2 diabetes?
Factors that contribute to the severity of hypoglycemia in patients with type 2 diabetes include increasing cognitive decline, treatment with insulin or insulin secretagogues, problems with kidney or hepatic function, increased duration of diabetes, older age and frailty, cognitive impairment, hypoglycemia unawareness/impaired counterregulatory response, impaired behavioral response to hypoglycemia due to physical or intellectual disability, use of alcohol, polypharmacy, including ACE inhibitors, ARBs, and nonselective beta-blockers, and a history of a severe hypoglycemic event.
What are some microvascular complications of diabetes?
Some microvascular complications of diabetes are retinopathy, nephropathy, and neuropathy (which may contribute to diabetic foot ulcer).
What is the leading cause of preventable blindness in adults with diabetes?
Retinopathy is the leading cause of preventable blindness in adults with diabetes.
What factors are associated with an increased risk of macrovascular events in patients with type 2 diabetes?
Older age, older age at diagnosis, and longer diabetes duration are associated with an increased risk of macrovascular events in patients with type 2 diabetes.
What are the macrovascular complications of type 2 diabetes?
The macrovascular complications of type 2 diabetes include cardiovascular disease, stroke, and peripheral arterial disease (PAD) of lower extremities.
What is the recommended consideration for patients above 75 years old who are not on statin therapy?
Consider initiating moderate-intensity statin therapy after discussing potential risks and benefits (ADA Grade C).
What should be done in patients who do not tolerate the intended dose of statin?
Adjust to the maximally tolerated dose (ADA Grade E).
What is the recommended lipid-lowering drug therapy for primary prevention of major coronary events in patients with diabetes?
The ADA recommends using moderate-intensity statins in combination with lifestyle therapy in adults aged 40-75 years without cardiovascular risk factors.
When should high-intensity statin therapy be considered for lipid-lowering in patients with diabetes?
High-intensity statin therapy is suggested for patients aged 40-75 years at increased cardiovascular risk (especially patients with multiple cardiovascular risk factors and LDL cholesterol ≥ 70 mg/dL).
What is the recommended LDL goal for patients receiving high-intensity statin therapy for lipid-lowering in diabetes?
The target LDL goal is < 70 mg/dL for patients aged 40-75 years at increased cardiovascular risk (especially patients with multiple cardiovascular risk factors and LDL cholesterol ≥ 70 mg/dL).
What additional therapies can be considered for patients receiving maximally tolerated statin therapy and still have LDL cholesterol ≥ 70 mg/dL?
For patients aged 40-75 years at increased cardiovascular risk (especially patients with multiple cardiovascular risk factors and LDL cholesterol ≥ 70 mg/dL), adding ezetimibe or a pro-protein convertase subtilisin-kexin type 9 (PCSK9) inhibitor to maximally tolerated statin therapy can be considered.
What lifestyle modifications are recommended to improve the lipid profile in adults with diabetes and reduce the risk of atherosclerotic cardiovascular disease?
The recommended lifestyle modifications include losing weight if appropriate, using a Mediterranean-style or Dietary Approaches to Stop Hypertension (DASH) eating pattern, reducing intake of saturated fat, trans fat, and cholesterol, increasing intake of omega-3 fatty acids, fiber, and plant stanols/sterols, and increasing physical activity.
What are some recommended lifestyle modifications for managing dyslipidemia in adults with diabetes?
Some recommended lifestyle modifications include losing weight if appropriate, adopting a Mediterranean-style or Dietary Approaches to Stop Hypertension (DASH) eating pattern, reducing intake of saturated fat, trans fat, and cholesterol, increasing intake of omega-3 fatty acids, fiber, and plant stanols/sterols, and increasing physical activity.
What are some lifestyle modifications recommended to improve lipid profile in adults with diabetes?
Some lifestyle modifications recommended to improve lipid profile in adults with diabetes include losing weight if appropriate, using a Mediterranean-style or Dietary Approaches to Stop Hypertension (DASH) eating pattern, reducing intake of saturated fat, trans fat, and cholesterol, increasing intake of omega-3 fatty acids, fiber, and plant stanols/sterols, and increasing physical activity.
What does the ADA recommend for weight loss medications in patients with type 2 diabetes and a BMI ≥ 27 kg/m2?
The ADA recommends weight loss medications as effective adjuncts to diet, physical activity, and behavioral counseling for patients who respond sufficiently to the medication.
How is a sufficient response to weight loss medication defined by the ADA?
A sufficient response to weight loss medication is typically defined as > 5% weight loss after 3 months of use, according to the ADA.
What should be considered for patients with an insufficient response to weight loss medication or safety/tolerability issues?
For patients with an insufficient response to weight loss medication (< 5% weight loss after 3 months of use) or safety/tolerability issues, discontinuation of the medication and evaluation of alternative medications or treatment approaches should be considered, according to the ADA.
What is the potential benefit of using weight loss medications in patients with type 2 diabetes and a BMI ≥ 27 kg/m2?
The potential benefit of using weight loss medications in patients with type 2 diabetes and a BMI ≥ 27 kg/m2 is additional weight loss, which is likely with continued use, according to the ADA.
What are the lower glycemic goals for older adults who are otherwise healthy and have few coexisting chronic illnesses and intact cognitive and functional status?
HbA1c < 7%-7.5% (53-58 mmol/mol)
What are the less stringent glycemic goals for older adults with multiple coexisting chronic illnesses, cognitive impairment, or functional dependence?
HbA1c < 8% (64 mmol/mol)
What should be avoided in older adults with relaxed glycemic goals as part of individualized care?
Hyperglycemia leading to symptoms and risk of acute hyperglycemia complications
What are the certain treatments common in older adults that may falsely increase or decrease HbA1c?
Hemodialysis, erythropoietin therapy, or transfusion
What are some clinical complications and comorbidities associated with type 2 diabetes in elderly patients?
Some clinical complications and comorbidities associated with type 2 diabetes in adults include impaired cognitive and renal function, slowed hormonal regulation and counterregulation, slowed intestinal absorption, suboptimal hydration, variable appetite and nutritional intake, and polypharmacy.
What are the potential effects of polypharmacy in patients with type 2 diabetes?
Polypharmacy in patients with type 2 diabetes can lead to increased medication interactions, higher risk of adverse drug events, decreased adherence to treatment plans,and potentially worsened glycemic control.
According to ADA recommendations, what is the preferred initial pharmacologic agent for older adults with type 2 diabetes?
Metformin is the preferred initial pharmacologic agent for older adults with type 2 diabetes.
What is the recommendation for assessing and managing episodes of hypoglycemia in older adults with type 2 diabetes?
Assess and manage episodes of hypoglycemia at routine office visits.
What is the recommendation regarding overtreatment of diabetes in older adults?
Avoid overtreatment of diabetes, which is common in older adults.
What factors should be considered in older adults to determine targets and therapeutic approaches for diabetes management?
Consider the assessment of functional (self-management abilities), medical, psychological, and social geriatric domains in older adults.
What is one of the recommendations for improving efficacy, durability of treatment effect, and benefits for weight and hypoglycemia with insulin therapy?
Combination therapy with a GLP-1 receptor agonist is recommended.
According to ADA guidelines, should metformin be continued upon initiation of insulin therapy?
Yes, metformin should be continued for ongoing glycemic and metabolic benefit unless contraindicated or not tolerated.
What are the clinical findings that should prompt evaluation for possible overbasalization with insulin therapy?
Clinical findings that should prompt evaluation for possible overbasalization with insulin therapy include: requiring reevaluation to further individualize therapy.
Consideration of early introduction of insulin is recommended in patients with what symptoms?
Weight loss or other evidence of ongoing catabolism and symptomatic hyperglycemia (such as polyuria or polydipsia).
HbA1c > 10% (86 mmol/mol) or blood glucose levels ≥ 300 mg/dL (16.7 mmol/L) (Weak recommendation) until glucotoxicity resolves, at which time it is often possible to simplify regimen
According to ADA guidelines, what are the criteria for considering early introduction of insulin in patients with diabetes mellitus type 2?
HbA1c > 10% (86 mmol/mol) or blood glucose levels ≥ 300 mg/dL (16.7 mmol/L).
What is the recommended injectable therapy as the first option for patients with diabetes mellitus type 2 who have weight loss or other evidence of ongoing catabolism?
Insulin.
What type of therapy is often needed for patients with type 2 diabetes who require greater glucose lowering than can be achieved with oral agents alone?
Injectable therapy (such as GLP-1 receptor agonists and/or insulin).
According to ADA guidelines, why are GLP-1 receptor agonists preferred over insulin when possible for patients who require greater glucose lowering than can be achieved with oral agents alone?
Due to their favorable effects on weight and hypoglycemia risk.
What is the recommended approach for adults with type 2 diabetes who have HbA1c levels 1.5%-2% above target?
Early combination therapy may be appropriate in patients presenting with HbA1c levels 1.5%-2% above target.
What factors are considered in choosing an additional medication for combination therapy in adults with type 2 diabetes?
Choice of additional medication is based on presence of comorbidities, risk of adverse drug effects, safety, tolerability, and cost.
How much reduction in HbA1c can be expected when adding a new class of noninsulin drugs to initial therapy in type 2 diabetes?
Each new class of noninsulin drugs added to initial therapy is reported to reduce HbA1c by 0.7%-1%.
Which medications have very high weight-loss efficacy for patients with type 2 diabetes and overweight or obesity?
GLP-1 agonist semaglutide or dual GIP/GLP-1 agonist tirzepatide.
What are some agents with high weight-loss efficacy for patients with type 2 diabetes and overweight or obesity?
GLP-1 agonists dulaglutide or liraglutide.
What are some agents/regimens with very high efficacy for achieving glycemic control in adults with type 2 diabetes?
GLP-1 agonists dulaglutide (high-dose) and semaglutide, dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonist tirzepatide, insulin oral combination therapy, and injectable combinations (GLP-1 receptor agonist plus insulin)
What are some agents/regimens with high efficacy for achieving glycemic control in adults with type 2 diabetes?
GLP-1 agonists exenatide, liraglutide, and lixisenatide, metformin, SGLT2 inhibitors, sulfonylureas, thiazolidinediones
What are some agents/regimens with intermediate efficacy for achieving glycemic control in high-risk patients with type 2 diabetes?
Dipeptidyl peptidase IV (DPP-4) inhibitors
What is the recommended treatment for patients with type 2 diabetes and diabetic kidney disease with an estimated GFR ≥ 20 mL/minute/1.73 m2 and urinary albumin ranging from normal to 200 mg/g?
A SGLT2 inhibitor should be used to reduce progression of chronic kidney disease and risk for cardiovascular events (ADA Grade B).
What additional treatment options are recommended for patients with type 2 diabetes and diabetic kidney disease with an estimated GFR ≥ 20 mL/minute/1.73 m2?
For patients with type 2 diabetes and diabetic kidney disease with an estimated GFR ≥ 20 mL/minute/1.73 m2, a SGLT2 inhibitor, a GLP-1 receptor agonist, or a nonsteroidal mineralocorticoid receptor antagonist (if estimated GFR ≥ 25 mL/minute/1.73 m2) can be considered to reduce cardiovascular risk (ADA Grade A).
What is the recommended treatment for patients with chronic kidney disease and albuminuria who are at increased risk for cardiovascular events or chronic kidney disease progression?
A nonsteroidal mineralocorticoid receptor antagonist (finerenone) should be used to reduce chronic kidney disease progression and cardiovascular events (ADA Grade A).
What is the estimated GFR threshold for considering a nonsteroidal mineralocorticoid receptor antagonist as an additional treatment for patients with type 2 diabetes and diabetic kidney disease?
An estimated GFR of ≥ 25 mL/minute/1.73 m2 is the threshold for considering a nonsteroidal mineralocorticoid receptor antagonist as an additional treatment (ADA Grade A).
What type of inhibitors are preferred for patients with stable heart failure?
SGLT2 inhibitors
In patients with heart failure, what should be the estimated glomerular filtration rate (GFR) if metformin is to be used?
GFR > 30 mL/minute/1.73 m2
Why should thiazolidinediones not be recommended in patients with symptomatic heart failure?
Due to the association with increased risk of heart failure
What are the treatment options for patients with or at high risk for atherosclerotic cardiovascular disease?
GLP-1 receptor agonists or SGLT2 inhibitors with demonstrated benefit
What treatment option can be considered if HbA1c remains above target in patients with high risk for atherosclerotic cardiovascular disease?
Combination treatment with both a GLP-1 receptor agonist and an SGLT2 inhibitor
What alternative treatment option can be added if combination treatment is not suitable for patients with high risk for atherosclerotic cardiovascular disease?
Sglt2 + glp1
Low-dose thiazolidinedione
What are the patient criteria for using SGLT2 inhibitors and/or GLP-1 receptor agonists in type 2 diabetes?
Patients with type 2 diabetes and established atherosclerotic cardiovascular disease or indicators of high cardiovascular risk, heart failure, or established kidney disease.
What is the recommended cardiovascular risk reduction strategy for patients with type 2 diabetes?
Using a sodium-glucose cotransporter-2 (SGLT2) inhibitor and/or a glucagon-like peptide-1 (GLP-1) receptor agonist with demonstrated cardiovascular disease benefit as part of the glucose lowering regimen.
What is the first-line therapy for the initial pharmacologic management of type 2 diabetes in adults?
The first-line therapy for the initial pharmacologic management of type 2 diabetes in adults is metformin or other agents, alone or in combination.
What factors should be considered when choosing the first-line therapy for type 2 diabetes in adults?
The choice of first-line therapy for type 2 diabetes in adults should depend on patient comorbidities, patient-centered treatment factors, management needs, healthy lifestyle behaviors, education and support for diabetes self-management, avoidance of clinical inertia, and social determinants of health.
A
A
According to the ADA, how often should medication regimen and medication-taking behavior be evaluated?
Medication regimen and medication-taking behavior should be evaluated every 3-6 months.
What type of exercises are encouraged for older adults with type 2 diabetes?
Regular exercise including aerobic activity, weight-bearing exercise, and/or resistance training.
How often is flexibility and balance training recommended for older adults with type 2 diabetes?
2-3 times per week.
What are some examples of exercises that can be included to increase flexibility, muscular strength, and balance in older adults with type 2 diabetes?
Yoga and tai chi.
According to the American Diabetes Association, how many minutes of moderate to vigorous intensity aerobic physical activity should adults with type 2 diabetes perform per week?
Adults with type 2 diabetes should perform at least 150 minutes/week of moderate to vigorous intensity aerobic physical activity.
How many days per week should physical activity be spread over for adults with type 2 diabetes?
Physical activity should be spread over at least 3 days per week for adults with type 2 diabetes.
AND LESS THAN 2 DAYS WITHOUT EXERCISES
How many minutes per week of high-intensity or interval training may be sufficient for younger, more physically fit persons with type 2 diabetes?
For younger, more physically fit persons with type 2 diabetes, high-intensity or interval training for shorter durations of at least 75 minutes per week may be sufficient.
According to the ADA, should patients with diabetes limit their sodium consumption?
Yes, patients with diabetes are advised to limit their sodium consumption to less than 2,300 mg/day.
What does the ADA recommend regarding the routine use of micronutrients and herbal supplements for glycemic control in patients with diabetes?
The ADA does not recommend routine use of micronutrients and herbal supplements for glycemic control due to insufficient evidence for improving diabetes outcomes in patients without underlying deficiencies.
Why should beta-carotene supplementation be avoided in patients with diabetes?
Beta-carotene supplementation should be avoided as it is associated with increased risk of lung cancer and cardiovascular mortality according to the ADA.
A
A
A
A
Why is it important to monitor glucose levels after drinking alcoholic beverages?
To reduce the risk of hypoglycemia
What type of diet is recommended to improve glucose metabolism and reduce cardiovascular disease risk in individuals with type 2 diabetes?
A Mediterranean-style diet rich in monounsaturated and polyunsaturated fats.
What foods are recommended to prevent or treat cardiovascular disease in individuals with type 2 diabetes?
Foods rich in omega-3 fatty acids such as fatty fish, nuts, and seeds.
What is the ADA recommendation for nutrition in patients with type 2 diabetes?
The ADA recommends individualizing macronutrient intake based on total calorie and metabolic goals.